Verve Therapeutics, Inc. (NASDAQ:VERV) Given Consensus Rating of "Buy" by Analysts

Verve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report) has been given an average rating of "Buy" by the six brokerages that are covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $25.75.

A number of analysts have commented on VERV shares. Cantor Fitzgerald upgraded Verve Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Tuesday, April 15th. Canaccord Genuity Group lifted their price objective on shares of Verve Therapeutics from $32.00 to $39.00 and gave the company a "buy" rating in a research note on Tuesday, April 15th. HC Wainwright increased their price objective on shares of Verve Therapeutics from $15.00 to $25.00 and gave the company a "buy" rating in a research note on Monday, April 14th. William Blair reaffirmed an "outperform" rating on shares of Verve Therapeutics in a research report on Friday, February 21st. Finally, Royal Bank of Canada decreased their target price on Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating for the company in a research note on Tuesday, March 4th.

Verve Therapeutics Price Performance

Shares of VERV traded down $0.24 during mid-day trading on Wednesday, reaching $4.39. The company had a trading volume of 587,477 shares, compared to its average volume of 1,846,390. Verve Therapeutics has a twelve month low of $2.86 and a twelve month high of $9.31. The company's 50-day moving average is $4.78 and its 200-day moving average is $5.86. The company has a market capitalization of $391.25 million, a P/E ratio of -1.78 and a beta of 1.82.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.35) EPS for the quarter, beating analysts' consensus estimates of ($0.71) by $0.36. The company had revenue of $32.98 million during the quarter, compared to analysts' expectations of $7.13 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. As a group, equities analysts expect that Verve Therapeutics will post -2.49 EPS for the current fiscal year.

Institutional Trading of Verve Therapeutics

A number of hedge funds have recently made changes to their positions in VERV. GAMMA Investing LLC lifted its stake in shares of Verve Therapeutics by 189.7% in the fourth quarter. GAMMA Investing LLC now owns 6,054 shares of the company's stock valued at $34,000 after buying an additional 3,964 shares in the last quarter. IFP Advisors Inc grew its position in Verve Therapeutics by 823,700.0% during the fourth quarter. IFP Advisors Inc now owns 8,238 shares of the company's stock valued at $47,000 after acquiring an additional 8,237 shares during the last quarter. BNP Paribas Financial Markets purchased a new position in shares of Verve Therapeutics in the fourth quarter worth $50,000. KFG Wealth Management LLC purchased a new stake in shares of Verve Therapeutics during the first quarter worth about $46,000. Finally, Cambridge Investment Research Advisors Inc. purchased a new stake in Verve Therapeutics in the 1st quarter worth approximately $47,000. 97.11% of the stock is owned by institutional investors and hedge funds.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.